BlueCross BlueShield Federal Employee Program

RETACRIT (epoetin alfa)
PRIOR APPROVAL REQUEST

Send completed form to:
FAX: 855-895-3504
FOR URGENT FAX: 844-244-0226

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

Patient Information (required)			**Provider Information (required)**		
Date:			Provider Name:		
Patient Name:			Specialty:	NPI:	
Date of Birth:	Sex: ❑Male ❑Female		Office Phone:	Office Fax:	
Street Address:			Office Street Address:		
City:	State:	Zip:	City:	State:	Zip:
Patient ID: **R**			Physician Signature:		
PHYSICIAN COMPLETES					

Retacrit (epoetin alfa-epbx)

****Check www.fepblue.org/formulary to confirm which medication is part of the patient's benefit**

NOTE: Form must be completed in its **entirety** for processing

Note: Approval cannot be given unless all lab values are provided for the diagnosis chosen

Is this request for brand or generic? ❑Brand ❑Generic

1. Is Retacrit being used in combination with another erythropoiesis stimulating agent (ESA)? ❑Yes* ❑No
   If YES, please specify the medication: _____
2. Has the patient been on Retacrit continuously for the last **4 months**, excluding samples? ❑Yes ❑No*
   If NO, is Retacrit being requested as a change from Procrit to allow the member access to their copay benefit? ❑Yes ❑No
3. What is the patient's diagnosis?
   - ❑ Allogeneic bone marrow transplantation
   - ❑ Anemia associated with Hepatitis C (HCV) treatment
   - ❑ Myelodysplastic syndrome
   - ❑ Anemia associated with Rheumatoid Arthritis (RA)/rheumatic disease
   - ❑ Anemia associated with chronic renal failure
     a. What is the patient's serum ferritin level in nanograms per milliliter (ng/mL)? _____ ng/mL
     b. Have both the serum ferritin level and hemoglobin been obtained within the past 3 months? ❑Yes ❑No
     c. Has the patient been on Retacrit continuously for the last **4 months**, excluding samples? ***Please select answer below***
     - ❑ **NO** – this is **INITIATION** of therapy, please answer the following questions:
       i. Is the patient on dialysis? ***Please select answer below:***
       - ❑ **Yes**: What is the patient's *hemoglobin level in grams per deciliter (g/dL)? _____ g/dL
         If hemoglobin level is greater than or equal to 10 g/dL, will the dose be held or reduced until the hemoglobin level is less than 10 grams per deciliter (g/dL)? ❑Yes ❑No
       - ❑ **No**: What is the patient's *hemoglobin level in grams per deciliter (g/dL)? _____ g/dL
         If hemoglobin level is greater than or equal to 11g/dL, will the dose be held or reduced until the hemoglobin level is less than 11 grams per deciliter (g/dL)? ❑Yes ❑No
     - ❑ **YES** – this is a PA renewal for **CONTINUATION** of therapy, please answer the following question(s):
       i. What is the patient's *hemoglobin level in grams per deciliter (g/dL)? _____ g/dL
       If hemoglobin level greater than 11 g/dL, will the dose be held or reduced until the hemoglobin level is less than or equal to 11 grams per deciliter (g/dL)? ❑Yes ❑No
   - ❑ Anemia in patients scheduled to undergo elective, non-cardiac, nonvascular surgery
     a. What is the patient's hemoglobin level in grams per deciliter (g/dL)? _____ g/dL

PLEASE PROCEED TO PAGE 2 FOR ADDITIONAL DIAGNOSES

BlueCross BlueShield Federal Employee Program

EPOETIN ALFA
PRIOR APPROVAL REQUEST

Send completed form to:
FAX: 855-895-3504
FOR URGENT FAX: 844-244-0226

PAGE 2 - PHYSICIAN COMPLETES

Patient Name: _____ **DOB:** _____ **Patient ID: R** _____

❑ Anemia secondary to chemotherapy

a. Is the patient receiving concomitant myelosuppresive therapy? ❑Yes ❑No

b. Are there 2 or more additional months of chemotherapy planned for the patient? ❑Yes ❑No

c. Does the prescriber agree to discontinue Retacrit upon completion of the chemotherapy? ❑Yes ❑No

d. Does the prescriber agree that transfusions are **NOT** an option for treatment (i.e., end stage organ failure, chronic kidney disease (CKD), and high risk bacterial infections)? ❑Yes ❑No

❑ Anemia secondary to zidovudine-treated Human Immunodeficiency Virus (HIV) patients

a. Are the patient's endogenous serum erythropoietin levels less than or equal to 500 milliunits per milliliter (mU/mL)? ❑Yes ❑No

❑ Other diagnosis ***(please specify):*** _____